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Key messages 
 A mildly elevated platelet count may indicate underlying cancer 
 The 1 year cancer incidence was 5.1% with a platelet count of 375 – 399 x 109/l 
 This exceeds the 3% threshold for investigation for cancer (NICE NG12) 
 These findings should prompt GPs to suspect cancer where they may not have done 
 Cancer incidence was higher in males than in females 
 Firm recommendation would require these results to be replicated on a larger scale
Abstract 
Background 
A platelet count >400×109/l (i.e. thrombocytosis) is a recently discovered risk marker of cancer. The risk 
of undiagnosed cancer in patients with thrombocytosis is 11.6% for men and 6.2% for women; well above 
the 3% risk threshold set by NICE for cancer investigation. Patients with a platelet count at the upper end 
of the normal range (325-400x109/l) could be at increased risk of undiagnosed malignancy.  
 
Objective 
To quantify the risk of an undiagnosed cancer in patients with a platelet count at the upper end of the 
normal range. 
 
Methods  
A primary care-based cohort study using Clinical Practice Research Datalink (CPRD) data from 2000 - 
2013. The study sample comprised 2704 individuals stratified by platelet count: 325-349 x 109/l; 350-374 
x 109/l; 375-399 x 109/l. Incident cancer diagnoses in the year following that platelet count were obtained 
from patient records.  
 
Results 
Cancer incidence rose with increasing platelet count: 2.6% (95% CI 1.9 to 3.6) in subjects with a count of 
325-349x109/l; 3.7% (95% CI 2.5 to 5.3) in subjects with a count of 350-374x109/l; and 5.1% (95% CI 3.4 
to 7.5) in those with a count of 375-399x109/l. Colorectal cancer was the most commonly diagnosed type 
in all three groups. Cancer incidence was consistently higher in males than in females.  
 
Conclusion 
These results suggest that clinicians should consider cancer in patients with a platelet count >375x109/l, 
and review the reasons for blood testing and any additional reported symptoms. Until these results are 
replicated on a larger scale, recommendations for clinical action cannot be made. 
 
 
Background 
Cancer survival in the UK is improving, but generally lags behind that in other European countries.1,2 
Improving earlier diagnosis has been identified as a key strategy to improve survival.1 A range of research 
and policy initiatives have aimed to achieve this including public awareness campaigns and two week 
wait clinics. A valuable approach to achieving earlier diagnosis is to identify signs and symptoms that are 
associated with underlying malignancy to help GPs select patients for referral for definitive diagnostic 
testing. Previous approaches to improving cancer diagnosis have included the production of Risk 
Assessment Tools (RATs) which present the risk of cancer associated with various clinical signs and 
symptoms. One such sign is thrombocytosis (high platelet count).3 In the UK, most laboratories report a 
platelet count of 400x109/l as being the upper end of normal, although lower values have been proposed.4 
Our recent study reported that the positive predictive value of thrombocytosis for detecting any cancer in 
those aged 40 years and over is 11.6% (95% confidence interval 11.0 to 12.3) in men, and 6.2% (95% CI 
5.9 to 6.5) in women.3 This risk value far exceeds the 3% threshold set in the UK by the National Institute 
for Health and Care Excellence (NICE) at which patients are recommended for referral for possible 
cancer.5 In that study, even mildly elevated platelet counts had a positive predictive value for cancer 
above 3%. Patients with a platelet count at the upper end of the normal range may also be at increased 
risk of cancer; identifying these patients in primary care may be the first ‘clue’ to an undiagnosed 
malignancy which could help to achieve earlier diagnosis, before other symptoms have developed. In this 
study, we aimed to quantify the risk of undiagnosed cancer in patients with a platelet count at the upper 
end of the normal range. 
 
Methods 
Data sources  
Electronic medical records from the Clinical Practice Research Datalink (CPRD, www.cprd.co.uk) linked 
with English National Cancer Registration Service (NCRS) data.6 The CPRD compiles patient records 
from UK primary care, and holds data on approximately 7% of the UK population. The NCRS for England 
gathers patient data from screening and imaging services, secondary care patient administration 
systems, and Hospital Episode Statistics.  
 
Study population 
The study sample was a randomly selected 10,000 from the CPRD database (the comparison group from 
our earlier study3) who met the following inclusion criteria: 
 First platelet count from 2000 to 2013 was from 150 ×109/l to 399 x 109/l 
 Aged 40 years at the time of the platelet count 
 No cancer diagnosis recorded prior to that platelet count 
Exclusion criteria included: 
 Aged under 40 years at index date 
 Diagnosed with non-melanoma skin cancer (commonly under recorded) after index date  
From this sample, patients were selected for the present study who had a platelet count from 325 × 109/l 
to 399 x 109/l. The first qualifying platelet count in the study period was designated the ‘index date’. 
Subjects were stratified into three sub-groups:  
 Group 1: 325 – 349 x 109/l 
 Group 2: 350 – 374 x 109/l 
 Group 3: 375 – 399 x 109/l 
These ranges were chosen to be narrow enough to enable clinically useful indicators of when a platelet 
count should prompt further action for suspected cancer, whilst being wide enough to maintain 
reasonable sample sizes. Subjects were excluded if they had a cancer record prior to their platelet count 
index date. 
 
Study outcomes and analyses 
New cancer diagnoses were determined by searching CPRD records in the year after the platelet index 
date for any of 2,134 cancer-related codes, organized into 23 common sites. New diagnoses were also 
obtained from NCRS records; the earliest record was taken as the date of diagnosis.  
The one-year cancer incidence (and 95% confidence intervals) was estimated for groups 1–3. The cancer 
site was identified; where more than one site was recorded, the earliest record was taken as the primary 
site, and only one cancer diagnosis was recorded per individual. The results were stratified by sex in each 
group.  
It is not possible to determine from CPRD data why blood tests were ordered. Patients’ records in the 3 
weeks before the index date were searched for codes for single symptoms that should prompt urgent 
referral in the most recent NICE guidance (NG12).5 The proportion of subjects with these “alarms” 
symptoms in the 21 days before their blood test was determined, and compared for subjects with and 
without a subsequent cancer diagnosis.  
Stata version 14.2 was used to execute all analyses.7 This paper conforms to STROBE reporting 
guidelines.8  
 Results 
The study sample included 2,704 individuals after exclusions (Figure 1). Group 1 (platelet count 325-
349x109/l) included 1,439 subjects, of whom 328 (22.8%) were male. The median age at the index date 
was 69.4 years (interquartile range (IQR): 58.3 to 79.2).  Cancer was diagnosed in 38 patients within one 
year, an incidence of 2.6% (95% CI 1.9 to 3.6) (Table 1). Colorectal (n=7, 18%) and lung (n=5, 13%) were 
the most commonly recorded cancers (Figure 2). 
Group 2 (350-374 x109/l) included 779 subjects (164 (21.1%) males). The median age at index date was 
72.0 (IQR: 59.2 to 80.9). Cancer was diagnosed in 29 patients within one year, an incidence of 3.7% 
(95% CI 2.5 to 5.3) (Table 1). Colorectal (n=9, 31%) and lung (n=3, 10%) cancers were also the most 
commonly diagnosed in this cohort (Figure 2). 
Group 3 (375-399 x109/l) included 486 subjects (118 (24.3%) male). The median age at index date was 
71.7 (IQR: 58.9 to 81.3). Cancer was diagnosed in 25 patients within one year, an incidence of 5.1% 
(95% CI 3.4 to 7.5) (Table 1). Colorectal was the most commonly diagnosed cancer in this cohort (n=7, 
28%), followed by lung and prostate cancers (for both, n=2, 7%) (Figure 2).  
When the groups were stratified by sex, the cancer incidence was consistently higher in men than in 
women (Table 2).  
In the 21 days before the index test, single symptoms that should trigger an urgent referral under NICE 
NG12 (so-called alarm symptoms)5 were recorded for 47 of the 2,704 (1.7%) patients. The proportion 
reporting an alarm symptom was greater in patients who developed cancer within 1 year of the index test 
compared to those who did not; 9/92 (9.8%, 95% CI 4.6 to 17.8) versus 38/2,612 (1.5%, 95% CI 1.0 to 
2.0) respectively.  
 
Discussion 
Cancer incidence increased with increasing platelet count; the risk exceeded 3% in subjects with a 
platelet count of 375 – 399 x109/l. Cancer incidence was consistently higher in men than in women, 
indicating that baseline platelet levels are higher in women than in men, or that benign causes of raised 
platelet counts are more common in women. The proportion of males in the sample was just above 20%; 
this suggests that a higher platelet count is more common in women than in men. The influence of sex on 
platelet count is poorly understood, and worthy of further research. Colorectal was the most commonly 
diagnosed cancer type; this is in contrast with our previous work on cancer incidence in patients with a 
platelet count of >400x109/l, in which lung was most commonly diagnosed.3 In that study, a much higher 
proportion of lung and colorectal cancers were diagnosed than would be expected given national 
incidence data (and a much lower proportion of breast and prostate cancers). In the present study, too 
few cancers were diagnosed in the sample to make similar comparisons.  
Comparison with existing literature 
This is the first study to consider cancer risk with a platelet count in the high normal range. All previous 
studies have used a threshold of 400 x 109/l when examining the clinical utility of platelet count in 
diagnosing cancer. In a recent systematic review, thrombocytosis was found to be an independent 
predictor of four types of cancer in studies of single cancer sites: lung, kidney, oesophago-gastric, and 
uterine cancer. 9  
Cancer incidence rose with increasing platelet count. Despite the small sample size, it appears that the 
relationship between cancer risk and platelet counts is monotonic, and begins well in the ‘normal’ range. 
The concept of a single threshold defining normality is semi-arbitrary, and based on distributions in the 
healthy population. Our study population – primary care patients who had a full blood count taken – is a 
selected population with presumably more ill-heath than the full general population. There are many and 
varied clinical reasons for taking a full blood count; indeed, at least a quarter of the adult population in any 
one year has this test.10 Although our data are from a selected population, having a blood test is unlikely 
to introduce any bias specifically towards patients who are suspected of having an undiagnosed cancer 
due to the wide range of reasons for testing. Therefore, it is very unlikely this effect can explain our 
results, particularly with the clear dose-response effect. 
In every platelet count group, males had higher cancer risk compared with females. This is supported by 
a study suggesting that the normal range for platelet count is higher in females than in males; in that 
study, the normal upper limit was proposed to be 362 × 109/l for males and 405 × 109/l for females, 
supporting our finding that a platelet count in the (350-400) × 109/l range should raise more of a red flag 
for males than for females.4 If our findings are replicated, it is likely that the threshold platelet count 
warranting consideration of cancer will be lower in males than in females. In all three groups, colorectal 
cancer was the most common cancer occurring within one year of the index platelet count. This differs 
from our previous study, of patients with a platelet count >400 x 109/l, where lung cancer was the most 
commonly diagnosed.3  
Strengths and limitations 
This study uses a robust data source, the CPRD, which has been used extensively in past studies of 
cancer risk markers.11–14 The use of NCRS data is a further strength, identifying incident cases that may 
have been unrecorded in the CPRD. Blood counts are electronically transmitted to the CPRD, reducing 
the risk of recording error. This study is based on a convenience sample of patients taken from a previous 
study,3  resulting in small sample sizes and wide confidence intervals for the risk estimates. The reasons 
why the blood tests were ordered in the sample are unknown; cancer may have been suspected prior to 
blood testing.  Cancer alarm symptoms accounted for a negligible proportion (1.7%) of all symptoms in 
the 3 weeks before the index test, suggesting that cancer was not suspected in the vast majority of 
patients having blood testing. Cohort 1 had a lower median age than the other two cohorts (69.4 in Cohort 
1, 72.0 and 71.7 in Cohorts 2 and 3, respectively) which may have had an impact on the lower proportion 
of cancer diagnoses in that Cohort. The sample in the present study was too small to investigate the 
effect of age on the relationship between platelet count and cancer diagnosis; future work should address 
this. 
Conclusions 
This study is small, but suggests that the risk of cancer in men with platelet counts >325 x 109/l exceeds 
3%. For women, the figure is 375 x 109/l, though for platelet values in the range 350-374 x 109/l the risk is 
2.8% (95% CI 1.6 to 4.4), still above the level at which patients would like investigation.15 This suggests 
that clinicians should consider a cancer diagnosis in patients with a platelet count above these values. 
This could lead to earlier diagnosis, potentially at an earlier disease stage, if the patient is referred for 
further investigation sooner than they would have been had the raised platelet count not been recognized 
as a risk marker. A clinician receiving a high-normal platelet count should review why the test was done, 
and what ongoing symptoms the patient is reporting. This finding is currently only a clue towards possible 
cancer. Until the findings are replicated in a much larger sample, and the specific cancers delineated in 
greater detail with data on stage at diagnosis, a blanket recommendation for investigation would be 
premature.  
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Figure 1: Patient flow diagram to show the number of subjects included in each of the 
platelet count groups, and the number excluded from the original study sample. 
Group 1: 325 – 349 x 109/l. Group 2: 350 – 374 x 109/l. Group 3: 375 – 399 x 109/l. 
 
Normal platelet count (n = 10000) 
Final sample (n = 2704) 
Platelet count normal range (n = 6,589) 
Pre-existing cancer (n = 472) 
Non-melanoma skin cancer (n = 75) 
Index date pre-2000 (n = 142) 
Aged <40 years at index (n = 18) 
Group 1 (n = 1,439) Group 2 (n =779) Group 3 (n = 486) 
  
 
Figure 2. Sites of cancer diagnoses for (a) male and (b) female patients diagnosed with cancer in each of 
the three platelet count groups. Group 1: 325 – 349 x 109/l. Group 2: 350 – 374 x 109/l. Group 3: 375 – 
399 x 109/l. 
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Table 1. Number of cancers diagnosed in each platelet count group during follow-up and the cancer 
incidence (%, 95% confidence interval). Group 1: 325 – 349 x 109/l. Group 2: 350 – 374 x 109/l. Group 3: 
375 – 399 x 109/l. 
 
Group Platelet count 
range (×109/l) 
Subjects  Number diagnosed with 
cancer within one year 
One year incidence % 
(95% CI) 
1 325–349 1,439 38 2.6 (1.9 to 3.6) 
2 350–374 779 29 3.7 (2.5 to 5.3) 
3 375–399 486 25 5.1 (3.4 to 7.5) 
 
  
Table 2. Numbers of cancers diagnosed in each platelet count group during follow-up and the cancer 
incidence for that group (%, 95% confidence interval), by sex. Group 1: 325 – 349 x 109/l. Group 2: 350 – 
374 x 109/l. Group 3: 375 – 399 x 109/l. 
 
Group Sex Subjects  Number diagnosed with 
cancer within one year 
One year incidence, % 
(95% CI) 
1 Men 328 15 4.6 (2.6 to 7.4) 
Women 1,111 23 2.1 (1.3 to 3.1) 
2 Men 164 12 7.3 (3.8 to 12.4) 
Women 615 17 2.8 (1.6 to 4.4) 
3 Men 118 10 8.5 (4.1 to 15.0) 
Women 368 15 4.1 (2.3 to 6.6) 
 
Figure legends 
Figure 1: Patient flow diagram to show the number of subjects included in each of the platelet count 
groups, and the number excluded from the original study sample. Group 1: 325 – 349 x 109/l. Group 2: 
350 – 374 x 109/l. Group 3: 375 – 399 x 109/l. 
Figure 2. Sites of cancer diagnoses for (a) male and (b) female patients diagnosed with cancer in each of 
the three platelet count groups. Group 1: 325 – 349 x 109/l. Group 2: 350 – 374 x 109/l. Group 3: 375 – 
399 x 109/l. 
 
